Remote monitoring may Fine-Tune heart failure meds faster

NCT ID NCT07518030

Disease control Sponsor: Azienda Unita Sanitaria Locale di Piacenza Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether telemedicine follow-up helps doctors adjust heart failure medications more effectively than standard in-person visits. Eighty adults with newly diagnosed heart failure with reduced ejection fraction will be randomly assigned to either remote monitoring or usual care. The main goal is to see if the telemedicine group achieves better medication optimization after six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: telemedicine-based follow-up
What this could lead to: If successful, this could show that remote monitoring and virtual check-ins help doctors fine-tune heart failure medications more quickly and safely than standard in-person visits.
What could go wrong: This is a small, early-stage trial with only 80 participants, so results may not apply to everyone. Telemedicine may not work as well for patients with limited digital skills or access.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: Participants must meet all of the following criteria: 1. Provision of written informed consent. 2. Age ≥18 years. 3. Recent diagnosis of HFrEF, defined according to ESC criteria, established in either an inpatient or outpatient setting. 4. No prior initiation of GDMT for HF at the time of enrollment, or treatment limited to a single agent with potential disease-modifying effects prescribed for a different clinical indication. 5. Availability of adequate digital literacy, either by the patient or a caregiver, defined as the ability to use electronic devices for remote communication (phone/video calls), transmission of vital parameters (body weight, blood pressure, heart rate), and interaction with digital health tools. In cases of insufficient patient digital skills, the presence of a caregiver with adequate digital competence is acceptable. 6. Any etiology of HF is eligible, including ischemic, valvular, primary or infiltrative cardiomyopathies, iatrogenic or toxic causes, and tachycardia-induced cardiomyopathy. Exclusion Criteria: * Ongoing treatment with two or more guideline-directed heart failure medications at the time of HFrEF diagnosis * Presence of severe comorbidities or clinical instability requiring prolonged or continuous hospital management * Estimated life expectancy \<12 months * Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure with reduced ejection fraction (hfref) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure with reduced ejection fraction (hfref)

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

1 site. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Remote monitoring may Fine-Tune heart failure meds faster

What the study statuses mean